FECAL CALPROTECTIN LEVELS AND PRESENCE OF HELICOBACTER PYLORI CO-INFECTION IN INDIVIDUALS WITH ENTEROBIASIS
DOI:
https://doi.org/10.58395/wsd73c30Keywords:
Enterobius vermicularis, Helicobacter pylori, fecal calprotectinAbstract
Enterobiasis, caused by the nematode Enterobius vermicularis, is the most common parasitic infection in Bulgaria and worldwide. It causes damage to the colonic mucosa and impaired local immunity, which can lead to a predisposition to other intestinal infections.
Faecal calprotectin is a non-invasive biomarker that can be used to distinguish between inflammatory and non-inflammatory bowel diseases. Scientific data show varying degrees of increase in some bacterial and viral infections, but data on parasitic infections are extremely scarce. Helicobacter pylori is a Gram-negative bacterium that colonises the intestinal mucosa. It is one of the most common bacteria, with infection mostly occurring during childhood and remaining undiagnosed for a long time. This can lead to severe damage to the gastric mucosa.
This study aimed to determine the levels of fecal calprotectin in patients with enterobiasis, and to assess its significance as a marker for intestinal inflammation caused by E. vermicularis, as well as the presence of concomitant infection with H. pylori.
The study included 124 people with confirmed Enterobius vermicularis, aged between 1 and 49 years. Calprotectin levels were determined using a commercial kit (LIAISON®, DiaSorin). The Helicobacter pylori test was performed using an automated immunoassay to qualitatively determine the presence of H. pylori antigen in fecal samples (LIAISON®, DiaSorin). Fecal samples from 20 healthy individuals were also tested in parallel to serve as a control group.
H. pylori was detected in fecal samples from 14.5% (n = 18) of Enterobius-infected individuals (compared to none of the healthy individuals), suggesting an increased susceptibility to co-infection with this bacteria among susceptible individuals. Significant elevated fecal calprotectin values were found in three individuals with enterobiasis and borderline values in 16 individuals, indicating the presence of moderate intestinal inflammation in some patients with enterobiasis.
Downloads
References
1. Kapel N., Ouni H., Benahmed N., Barbot-Trystram L. Fecal calprotectin for the diagnosis and management of inflammatory bowel diseases. Cl. and Trans. Gastroenterology. 2023; 14: e00617. https://doi.org/10.14309/ctg.0000000000000617. DOI: https://doi.org/10.14309/ctg.0000000000000617
2. Steinbakk M., Naess-Andresen C., Lingaas E. et al. Antimicrobial actions of calcium binding leucocyte L1 protein, calprotectin. Lancet. 1990; 336: 763-765. https://doi.org/10.1016/0140-6736(90)93237-j. DOI: https://doi.org/10.1016/0140-6736(90)93237-J
3. Xu K., Geczy C. Ifn-Gamma and TNF regulate macrophage expression of the chemotactic S100 protein S100A8. J. Immunol. 2000; 164: 4916-4923. https://doi.org/10.4049/jimmunol.164.9.4916. DOI: https://doi.org/10.4049/jimmunol.164.9.4916
4. Schmid K., Lügering N., Stoll R. Immunohistochemical demonstration of the calcium-binding proteins MRP8 and MRP14 and their heterodimer (27E10 antigen) in Crohn’s disease. Hum. Pathol. 1995; 26: 334-337. https://doi.org/10.1016/0046-8177(95)90067-5. DOI: https://doi.org/10.1016/0046-8177(95)90067-5
5. Gebhardt C., Riehl A., Durchdewald M. et al. Rage signaling sustains inflammation and promotes tumor development. J. Exp. Med. 2008; 205: 275-285. https://doi.org/10.1084/jem.20070679. DOI: https://doi.org/10.1084/jem.20070679
6. Røseth A., Schmidt P., Fagerhol M. Correlation between faecal excretion of Indium-111-labelled granulocytes and calprotectin, a granulocyte marker protein, in patients with inflammatory bowel disease. Scand. J. Gastroenterol. 1999; 34: 50-54. https://doi.org/10.1080/00365529950172835. DOI: https://doi.org/10.1080/00365529950172835
7. Jukic A., Bakiri L., Wagner E., Tilg H., Adolph T. Calprotectin: from biomarker to biological function. Gut. 2021; 70: 1978-1988. https://doi.org/10.1136/gutjnl-2021-324855. DOI: https://doi.org/10.1136/gutjnl-2021-324855
8. Chen C., Huang J., Chang C., Kong M. Fecal calprotectin as a correlative marker in clinical severity of infectious diarrhea and usefulness in evaluating bacterial or viral pathogens in children. J. Pediatr. Gastroenterol. Nutr. 2012; 55(5): 541-547. https://doi.org/10.1097/MPG.0b013e318262a718. DOI: https://doi.org/10.1097/MPG.0b013e318262a718
9. Lam Y., Warouw S., Wahani A., Manoppo J., Salendu P. Correlation between gut pathogens and fecal calprotectin levels in young children with acute diarrhoea. Paediatr. Indones. 2014: 54: 193-197. https://doi.org/10.14238/pi54.4.2014.193-7. DOI: https://doi.org/10.14238/pi54.4.2014.01
10. Rady H., Elkazazz A., Saftawy E., Abdelrazek N. Parasites and Helicobacter pylori in Egyptian Children with or without diabetes with gastrointestinal manifestations and high calprotectin level. J. Egypt. Soc. Parasitol. 2019; 49(1): 243-248. https://www.parasitology.eg.net/new. DOI: https://doi.org/10.21608/jesp.2019.68310
11. Raafat A, Abdel-Shafi IR, Ismail MAM, Amin NM. Efficacy of Fecal Calprotectin as a Marker for the Pathogenicity of Blastocystis hominis. J. Egypt. Soc. Parasitol. 2021; 51(3): 641–646. https://doi.org/10.21608/jesp.2021.210455. DOI: https://doi.org/10.21608/jesp.2021.210455
12. Warren J., Marshall B. Unidentified curved bacilli on gastric epithelium in active chronic gastritis. Lancet. 1983; 1(8336): 1273-1275. https://pubmed.ncbi.nlm.nih.gov/6134060/ DOI: https://doi.org/10.1016/S0140-6736(83)92719-8
13. Wroblewski L., Peek R., Wilson K. Helicobacter pylori and Gastric Cancer: Factors that modulate disease risk. Clin. Microbiol. Rev. 2010; 23: 713-739. https://doi.org/10.1128/CMR.00011-10. DOI: https://doi.org/10.1128/CMR.00011-10
14. Allaker R., Young K., Hardie J., Domizio P., Meadows N. Prevalence of Helicobacter pylori at oral and gastrointestinal sites in children: evidence for possible oral-to-oral transmission. Journal of Medical Microbiology. 2002; 51(4): 312-317. https://doi.org/10.1099/0022-1317-51-4-312. DOI: https://doi.org/10.1099/0022-1317-51-4-312
15. Kusters J., van Vliet A., Kuipers E. Pathogenesis of Helicobacter pylori infection. Clinical Microbiology Reviews. 2006; 19(3): 449-490. https://doi.org/10.1128/CMR.00054-05. DOI: https://doi.org/10.1128/CMR.00054-05
16. Gu, H. Role of flagella in the pathogenesis of Helicobacter pylori. Curr. Microbiol. 2017; 74: 863-869. https://doi.org/10.1007/s00284-017-1256-4. DOI: https://doi.org/10.1007/s00284-017-1256-4
17. Backert S., Tegtmeyer N., Fischer W. Composition, structure and function of the Helicobacter pylori cag pathogenicity island encoded type IV secretion System. Future Microbiol. 2015; 10: 955-965. https://doi.org/10.2217/fmb.15.32. DOI: https://doi.org/10.2217/fmb.15.32
18. Hatakeyama M. Structure and function of Helicobacter pylori CagA, the first-identified bacterial protein involved in human cancer. Proc. Jpn. Acad. Ser. 2017; 93: 196-219. https://doi.org/10.2183/pjab.93.013. DOI: https://doi.org/10.2183/pjab.93.013
19. Ali A., Hussaini K. Helicobacter pylori: A contemporary perspective on pathogenesis, diagnosis and treatment strategies. Microorganisms. 2024; 12: 222. https://doi.org/10.3390/microorganisms12010222. DOI: https://doi.org/10.3390/microorganisms12010222
20. Hunt R., Xiao S., Megraud F. et al. Helicobacter pylori in developing countries. World Gastroenterology Organisation global guideline, Journal of Gastrointestinal and Liver Diseases. 2011; 20(3): 299-304. Available from: https://www.jgld.ro/jgld/index.php/jgld/article/view/2011.3.14
21. Bateson M. Helicobacter pylori infection with age. The Lancet. 1992; 339(8801): 1121. https://doi.org/10.1016/0140-6736(92)90721-e. DOI: https://doi.org/10.1016/0140-6736(92)90721-E
22. Burkhart C., Burkhart C. Assessment of frequency, transmission, and genitourinary complications of enterobiasis (pinworms). Int. Journal of Dermatology. 2005; 44(10): 837-840. https://doi.org/10.1111/j.1365-4632.2004.02332.x. . DOI: https://doi.org/10.1111/j.1365-4632.2004.02332.x
23. Cook G. Enterobius vermicularis infection. Gut. 1994; 35(9): 1159-1162. https://doi.org/10.1136/gut.35.9.1159. DOI: https://doi.org/10.1136/gut.35.9.1159
24. Jardine M., Kokai G., Dalzell A. Enterobius vermicularis and colitis in children. J. Pediatr. Gastroenterol. Nutr. 2006; 43: 610-612. https://doi.org/10.1097/01.mpg.0000243425.01593.58. DOI: https://doi.org/10.1097/01.mpg.0000243425.01593.58
25. Ton H., Brandsnes O., Dale S. et al. Improved assay for fecal calprotectin. Clin. Chim. Acta. 2000; 292: 41-54. https://doi.org/10.1016/s0009-8981(99)00206-5. DOI: https://doi.org/10.1016/S0009-8981(99)00206-5
26. Joshi S., Lewis S., Creanor S. et al. Age-related faecal calprotectin, lactoferrin and tumour M2-PK concentrations in healthy volunteers. Ann. Clin. Biochem. 2010; 47: 259-263. https://doi.org/10.1258/acb.2009.009061. DOI: https://doi.org/10.1258/acb.2009.009061
27. Rugtveit J., Fagerhol M. Age-dependent variations in fecal calprotectin concentrations in children. J. Pediatr. Gastroenterol. Nutr. 2002; 34: 323-324. https://doi.org/10.1097/00005176-200203000-00022. DOI: https://doi.org/10.1002/j.1536-4801.2002.tb07637.x
28. Aykur M., Armagan G., Vardar R., Dagci H. Fecal calprotectin as a factor that supports the pathogenicity of Dientamoeba fragilis. Microbial Pathogenesis. 2020; 139: 103868. https://doi.org/10.1016/j.micpath.2019.103868. DOI: https://doi.org/10.1016/j.micpath.2019.103868
29. Shapiro M., Shah N., Sehgal S. Severely elevated fecal calprotectin in a pediatric patient with persistent giardiasis. Academic J. of Gastroenterology and Hepatology. 2021. Article ID 000542. https://doi.org/10.33552/AJGH.2021.02.000542. DOI: https://doi.org/10.33552/AJGH.2021.02.000542
30. Loke P., Lee S., Oyesola O. Effects of helminths on the human immune response and the microbiome. Mucosal Immunol. 2022; 15: 1224-1233. https://doi.org/10.1038/s41385-022-00532-9. DOI: https://doi.org/10.1038/s41385-022-00532-9
31. Akoolo L., Rocha S., Parveen N. Protozoan co-infections and paraite influence on the efficacy of vaccines against bacterial and viral pathogens. Front. Microbiol. 2022; 13: 1020029. https://doi.org/10.3389/fmicb.2022.1020029. DOI: https://doi.org/10.3389/fmicb.2022.1020029
32. Bashir S., Khan M. Overview of Helicobacter pylori infection, prevalence, risk factors, and its prevention. Advanced Gut and Mirobiome Research. 2023; Article ID 9747027. https://doi.org/10.1155/2023/9747027. DOI: https://doi.org/10.1155/2023/9747027
33. Burkitt M., Duckworth C., Williams J., Pritchard D. Helicobacter pylori-induced gastric pathology: insights from in vivo and ex vivo models. Disease Models & Mechanisms. 2017; 10(2): 89-104. https://doi.org/10.1242/dmm.027649. DOI: https://doi.org/10.1242/dmm.027649
34. Mărginean C., Melit L., Săsăran M. Traditional and modern diagnostic approaches in diagnosing pediatric Helicobacter pylori infection. Children. 2022; 9: 994. https://doi.org/10.3390/children9070994. DOI: https://doi.org/10.3390/children9070994
35. Goh K., Chan W. Shiota S., Yamaoka Y. Epidemiology of Helicobacter pylori infection and public health implications. Helicobacter. 2011; 16: 1-9. https://doi.org/10.1111/j.1523-5378.2011.00874.x. DOI: https://doi.org/10.1111/j.1523-5378.2011.00874.x
36. Hestvik E., Tylleskar T., Kaddu-Mulindwa D. et al., Helicobacter pylori in apparently healthy children aged 0-12 years in urban Kampala, Uganda: a community-based cross sectional survey. BMC Gastroenterology. 2010; 10: 62. https://doi.org/10.1186/1471-230X-10-62. DOI: https://doi.org/10.1186/1471-230X-10-62
37. Roma E., Miele E. Helicobacter pylori infection in paediatrics. Helicobacter. 2015; 20 (Supplement 1): 47-53. https://doi.org/10.1111/hel.12257. DOI: https://doi.org/10.1111/hel.12257
38. Abbas M., Sharif F., Osman S., Osman A., El Sanousi S., Magzoub M., Ibrahim M. Prevalence and associated symptoms of Helicobacter pylori infection among schoolchildren in Kassala State, East of Sudan. Interdiscip. Perspect. Infect. Dis. 2018; 2018: 4325752. https://doi.org/10.1155/2018/4325752. DOI: https://doi.org/10.1155/2018/4325752
39. Boyanova L., Hadzhiyski P., Markovska R., Yaneva P., Yordanov D., Gergova G., Mitov I. Prevalence of Helicobacter pylori is still high among symptomatic Bulgarian children. Acta Microbiol. Immunol. Hung. 2019; 66: 255-260. https://doi.org/10.1556/030.65.2018.053. DOI: https://doi.org/10.1556/030.65.2018.053
40. Szaflarska-Popławska A., Soroczynska-Wrzyszcz A. Prevalence of Helicobacter pylori infection among junior high school students in Grudziadz, Poland. Helicobacter. 2019; 24: e12552. https://doi.org/10.1111/hel.12552. DOI: https://doi.org/10.1111/hel.12552
41. Alexander S., Retnakumar R., Chouhan D., Devi T., Dharmaseelan S., Devadas K., Thapa N., Tamang J., Lamtha S., Chattopadhyay S. Helicobacter pylori in human stomach: the inconsistencies in clinical outcomes and the probable causes. Front. Microbiol. 2021; 12: 713955. https://doi.org/10.3389/fmicb.2021.713955. DOI: https://doi.org/10.3389/fmicb.2021.713955
42. Sipponen P., Hyvärinen H. Role of Helicobacter pylori in the pathogenesis of gastritis, peptic ulcer and gastric cancer. Scandinavian Journal of Gastroenterology. 1993. 28(sup196): 3-6. https://doi.org/10.3109/00365529309098333. DOI: https://doi.org/10.3109/00365529309098333
43. Laoraksawong P., Pansuwan P., Krongchon S., Pongpanitanont P., Janwan P. Prevalence of Enterobius vermicularis infections and associated risk factors among schoolchildren in Nakhon Si Tammarat, Tailand. Trop. Med. Health. 2020; 48: 83. https://doi.org/10.1186/s41182-020-00270-3. DOI: https://doi.org/10.1186/s41182-020-00270-3
44. Lohiya G., Tan-Figueroa L., Crinella F., Lohiya S. Epidemiology and control of enterobiasis in a developmental center. West. J. Med. 2000; 172: 305-308. https://doi.org/10.1136/ewjm.172.5.305. DOI: https://doi.org/10.1136/ewjm.172.5.305
45. Palmas C., Gabriele F., Conchedda M., Bortoletti G., Ecca A. Causality or coincidence: may the slow disappearance of helminths be responsible for the imbalances in immune control mechanisms? J. Helminthol. 2003; 77(2): 147-153. https://doi.org/10.1079/JOH2003176. DOI: https://doi.org/10.1079/JOH2003176
46. Cox F. Concomitant infections, parasites and immune responses. Parasitology. 2001; 122 Suppl: S23-38. https://doi.org/10.1017/s003118200001698x. DOI: https://doi.org/10.1017/S003118200001698X
Downloads
Published
Issue
Section
License
Copyright (c) 2026 Rumen Harizanov, Eleonora Kaneva, Desislava Velcheva (Author)
This work is licensed under a Creative Commons Attribution 4.0 International License.
